Pharmaxis : Application for quotation of securities - PXS
November 23, 2021 at 07:20 pm EST
Share
Application for quotation of +securities
Announcement Summary
For personal use only
Entity name
PHARMAXIS LTD
Announcement Type
New announcement
Date of this announcement
Wednesday November 24, 2021
The +securities to be quoted are:
+Securities issued as part of a transaction or transactions previously announced to the market in an Appendix 3B
Total number of +securities to be quoted
ASX +security
Number of +securities to
code
Security description
be quoted
Issue date
PXS
ORDINARY FULLY PAID
9,523,810
24/11/2021
Refer to next page for full details of the announcement
Application for quotation of +securities
1 / 6
Application for quotation of +securities
Part 1 - Entity and announcement details
For personal use only
1.1 Name of entity
PHARMAXIS LTD
We (the entity named above) apply for +quotation of the following +securities and agree to the matters set out in Appendix 2A of the ASX Listing Rules.
1.2
Registered number type
Registration number
ABN
75082811630
1.3
ASX issuer code
PXS
The announcement is New announcement
Date of this announcement
24/11/2021
Application for quotation of +securities
2 / 6
Application for quotation of +securities
Part 2 - Type of Issue
2.1 The +securities to be quoted are:
+Securities issued as part of a transaction or transactions previously announced to the market in an Appendix 3B
For personal use only
Previous Appendix 3B details:
Announcement Date and
Announcement Title
Selected Appendix 3B to submit quotation
Time
request
17-Nov-2021 10:13
New - Proposed issue of securities -
A placement or other type of issue
PXS
2.3a.2 Are there any further issues of +securities yet to take place to complete the transaction(s) referred to in the Appendix 3B?
No
Application for quotation of +securities
3 / 6
Application for quotation of +securities
Part 3A - number and type of +securities to be quoted where issue has previously been notified to ASX in an Appendix 3B
Placement Details
only
ASX +security code and description
PXS : ORDINARY FULLY PAID
Issue date
24/11/2021
use
Distribution Schedule
Provide a distribution schedule for the new +securities according to the categories set out in the left hand column -
including the number of recipients and the total percentage of the new +securities held by the recipients in each
category.
personalFor
Total percentage of +securities held
Number of +securities held
Number of holders
For example, to enter a value of 50%
please input as 50.00
1 - 1,000
%
1,001
- 5,000
%
5,001
- 10,000
%
10,001 - 100,000
%
100,001 and over
%
Application for quotation of +securities
4 / 6
Application for quotation of +securities
Issue details
Number of +securities to be quoted
9,523,810
For personal use only
Are the +securities being issued for a cash consideration?
Yes
In what currency is the cash consideration being paid? What is the issue price per +security?
AUD - Australian Dollar
AUD 0.10500000
Any other information the entity wishes to provide about the +securities to be quoted
Application for quotation of +securities
5 / 6
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Pharmaxis Limited published this content on 24 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 November 2021 00:19:08 UTC.
Syntara Limited, formerly Pharmaxis Ltd, is an Australia-based clinical-stage drug development company with a focus on blood-related cancers. The Companyâs highly productive drug discovery engine is driven by its expertise in amine oxidase inhibitors. Its lead candidate, PXS-5505, is used for the bone marrow cancer myelofibrosis, which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. The Company is also advancing both oral and topical pan-LOX inhibitors in scar prevention and scar modification programs. Its PXS-4728 is a SSAO/MAOB inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinsonâs by reducing neuroinflammation. The Companyâs other drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis, and cardiac fibrosis. It has developed two respiratory products: Bronchitol, for cystic fibrosis, and Aridol, a lung function test.